Search research articles
Contact Us
Filters
Showing results (121-130 of 145) with videos related to
Page
of 15
Sort By:
Cancers
|
July 2, 2021
Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy
Emilio Esteban, Francisco Exposito, Guillermo Crespo, et al.
Oncotarget
|
January 18, 2019
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
Paula Jiménez-Fonseca, Miguel Navarro Martín, Alberto Carmona-Bayonas, et al.
Revista Medica De Chile
|
December 18, 2014
[Recommendations of the Chilean Association for Digestive Endoscopy for the management of gastric pre-malignant lesions]
Antonio Rollán, Pablo Cortés, Alfonso Calvo, et al.
Disease Models & Mechanisms
|
December 6, 2021
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
Karmele Valencia, Cristina Sainz, Cristina Bértolo, et al.
Translational Lung Cancer Research
|
June 15, 2026
Long-term survival and biomarkers of immunotherapy in small cell lung cancer: a systematic review
Sandra Laguna, Amaya Sádaba, Idoia Morilla, et al.
Scientific Reports
|
October 30, 2019
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Maria Villalba, Esther Redin, Francisco Exposito, et al.
Journal for Immunotherapy of Cancer
|
March 4, 2021
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Esther Redin, Irati Garmendia, Teresa Lozano, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 21, 2022
YES1 Is a Druggable Oncogenic Target in SCLC
Esther Redin, Eva M Garrido-Martin, Karmele Valencia, et al.
Molecular Medicine (Cambridge, Mass.)
|
June 11, 2025
ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer
Mirian Gutiérrez, Irene Zamora, Raquel Iriarte, et al.
Journal for Immunotherapy of Cancer
|
August 2, 2022
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Celia Martín-Otal, Aritz Lasarte-Cia, Diego Serrano, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 145) with videos related to
Sort By:
Page
of 15
Cancers
|
July 2, 2021
Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy
Emilio Esteban, Francisco Exposito, Guillermo Crespo, et al.
Oncotarget
|
January 18, 2019
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
Paula Jiménez-Fonseca, Miguel Navarro Martín, Alberto Carmona-Bayonas, et al.
Revista Medica De Chile
|
December 18, 2014
[Recommendations of the Chilean Association for Digestive Endoscopy for the management of gastric pre-malignant lesions]
Antonio Rollán, Pablo Cortés, Alfonso Calvo, et al.
Disease Models & Mechanisms
|
December 6, 2021
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
Karmele Valencia, Cristina Sainz, Cristina Bértolo, et al.
Translational Lung Cancer Research
|
June 15, 2026
Long-term survival and biomarkers of immunotherapy in small cell lung cancer: a systematic review
Sandra Laguna, Amaya Sádaba, Idoia Morilla, et al.
Scientific Reports
|
October 30, 2019
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Maria Villalba, Esther Redin, Francisco Exposito, et al.
Journal for Immunotherapy of Cancer
|
March 4, 2021
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Esther Redin, Irati Garmendia, Teresa Lozano, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 21, 2022
YES1 Is a Druggable Oncogenic Target in SCLC
Esther Redin, Eva M Garrido-Martin, Karmele Valencia, et al.
Molecular Medicine (Cambridge, Mass.)
|
June 11, 2025
ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer
Mirian Gutiérrez, Irene Zamora, Raquel Iriarte, et al.
Journal for Immunotherapy of Cancer
|
August 2, 2022
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Celia Martín-Otal, Aritz Lasarte-Cia, Diego Serrano, et al.
Page
of 15